A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Summary

To determine the efficacy and safety of an oral drug (BGC20-0134) in patients with relapsing remitting multiple sclerosis. Specifically, the cumulative number of new gadolinium enhancing lesions after 24 weeks of treatment with BGC20-0134.

Timeline

Start

2009-11

Primary completion

2011-12

Completion

2011-12

Outcome

Outcome not reported

Stopped: “Lack of efficacy”

Drugs

Indications